Claire Lucas

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13

GMP-140 binding to neutrophils is inhibited by sulfated glycans.

Michael P. Skinner, Claire Lucas, Gordon F. Burns et al. · Journal of Biological Chemistry · 1991 · 199 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

Nonenzymatic Turnover of an<i>Erwinia carotovora</i>Quorum-Sensing Signaling Molecule

Joseph T. Byers, Claire Lucas, George P. C. Salmond et al. · Journal of Bacteriology · 2002 · 179 citations · Full text

Life Sciences, Microbiology, Cell Signaling +16

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Claire Lucas, Robert J. Harris, Athina Giannoudis et al. · Blood · 2011 · 139 citations · Full text

Medicine, Cancer Biology, Oncology +8

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

Athina Giannoudis, Andrea Davies, Claire Lucas et al. · Blood · 2008 · 128 citations · Full text

Medicine, Oncology, Pharmacokinetics +15